Recruiting

Early Phase 1

Autonomic NeuromodulationCharacterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

Sponsor:

University of Pennsylvania

Code:

NCT05377216

Conditions

Ventricular Tachycardia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Stellate Ganglion Block

Study Details

Brief summary:

Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.

Conditions

Ventricular Tachycardia

Study ID

NCT05377216

Start date

Sep 1, 2022

Status verified date

Nov, 2025

Completion date

Jul 1, 2027

Anticipated

Primary completion date

Jul 1, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Planned catheter based VT ablation
Age at least 18 years

Exclusion Criteria:

Pregnancy
Contraindication to SGB or VT ablation
Hypersensitivity of local anesthetic of amide type
Hemodynamic instability during the procedure prior to the study protocol

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Stellate ganglion block

All subjects will undergo stellate ganglion block during their VT ablation procedure

Interventions

Stellate Ganglion Block

Left sided percutaneous stellate ganglion block

Primary outcome measure

Ventricular Effective Refractory Period [ Time Frame: 30 minutes following stellate ganglion block ]

Central Contacts and Locations

Central contacts

Timothy Markman, MD

267-593-0103 timothy.markman@pennmedicine.upenn.edu

Locations

Hospital of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

More Information

Sponsor

University of Pennsylvania

Last update posted

Nov 21, 2025

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2025-11-21.